Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.68 |
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | PNP | P00491 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 5/20 | 0.57 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.55 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15798640 | 1.00 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL9116032 | 0.89 | HINT1 (0.66) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3970953 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3514472 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL17355882 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2014087 | 0.87 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL15338533 | 0.87 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL7111080 | 0.87 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL116165 | 0.87 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL11965261 | 0.87 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| WO-2025096203-A1 | TARGETING A CHIMERIC RNA FOR TREATING CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119375375-A | Method for detecting nucleotide, cap analogue and nucleic acid in vitro transcription product | 楷拓生物科技(苏州)有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| EP-4387596-A1 | LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387597-A1 | FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4367134-A1 | UTILIZATION OF ANTIBODIES TO SHAPE ANTIBODY RESPONSES TO AN ANTIGEN | Regeneron Pharmaceuticals, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024089633-A1 | RNA MOLECULES ENCODING RSV-F AND VACCINES CONTAINING THEM | PFIZER INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024064965-A2 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE (ARV) TECHNOLOGIES, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20030109484-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'ethynyl cytidine, uridine and guanosine derivatives | MCCARTHY JAMES R (US) | 2003-06-12 | — | — | US | disclosed |
| US-5977325-A | NUCLEOSIDE DERIVATIVES USEFUL AS ANTICARCINOGENIC/ANTITUMOR AGENTS AND VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5792841-A | ANTIVIRAL, ANTINEOPLASTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5616702-A | ANTITUMOR AGENTS, VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5607925-A | Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides | MERRELL PHARMACEUTICALS INC. (US) | 1997-03-04 | — | — | US | disclosed |
| US-5378693-A | Antitumor agents or viricides | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0372268-B1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL DOW PHARMA (US) | 1994-05-04 | — | — | EP | disclosed |
| CN-1022248-C | Novel 2'-halomethylidene, uridine and guanosine drivatives | MERRELL DOW PHARMA (US) | 1993-09-29 | — | — | CN | disclosed |
| EP-0372268-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-06-13 | — | — | EP | disclosed |
| CN-1042715-A | New 2 '-halogenated methylene, 2 '-vinylidene and 2 '-ethynyl cytidine, uridine and black glycoside derivates | MERRELL DOW PHARMA (US) | 1990-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109484-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'ethynyl cytidine, uridine and guanosine derivatives | UMPS, NUDT1, NUDT14 | HINT1 102/4885NT5E 77/4885GSK3A 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.